SEC Form 4 · accession 0002127814-26-000004
Scribe Therapeutics, Inc. · SCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin L. Oakes
Officer — President, CEO · Director · Other
Period of report
Mar 13, 2026
Accepted (ET)
Jul 27, 2026 · 9:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001853921
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $19.13 | Mar 13, 2026 | A | 12,969 | A | — | Mar 12, 2036 | Common Stock | 12,969 | 12,969 | D |
| Stock Option (Right to Buy)F3 | $15.00 | Jul 23, 2026 | A | 264,784 | A | — | Jul 22, 2036 | Common Stock | 264,784 | 264,784 | D |
| Performance-based Stock Option (Right to Buy)F4 | $15.00 | Jul 23, 2026 | A | 429,599 | A | — | Jul 22, 2036 | Common Stock | 429,599 | 429,599 | D |
Explanation of responses
- F1The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
- F2The option is fully vested.
- F3The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- F4The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.